Exelixis Announces Second Quarter 2019 Financial Results and Provides Corporate Update
– Total Revenue of $240.3 Million, Cabozantinib Franchise Revenue of $193.7 Million – – GAAP Diluted EPS of $0.25, Non-GAAP…
Pharmaceuticals, Biotechnology and Life Sciences
– Total Revenue of $240.3 Million, Cabozantinib Franchise Revenue of $193.7 Million – – GAAP Diluted EPS of $0.25, Non-GAAP…
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the…
– Companies will partner to advance small molecules in up to six discrete projects, including three existing programs against specific…
HAWTHORNE, N.Y.–(BUSINESS WIRE)–Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the…
PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify ESCC patients SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies…
– FDA approves Enstilar (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064%, for the topical treatment of plaque psoriasis in patients 12…
DUBLIN–(BUSINESS WIRE)–The “Global Cancer Stem Cell Therapy Market, Price, Dosage and Clinical Trial Insight 2025” clinical trials has been added…
ALACHUA, Fla.–(BUSINESS WIRE)–CTD Holdings, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease…
FDA 510(k) cleared Respiration Rate analytic adds to physIQ’s growing portfolio of FDA 510(k) algorithms Clearance allows physIQ to power…
REDWOOD CITY, Calif.–(BUSINESS WIRE)–#digimeds–Senior Vice President of US Market and Franchise Development at Proteus Digital Health® Olivia Ware has been…